Brussels, 14/03/2001 (Agence Europe) - The European Commission has sent a statement of objections to the American firm IMS HEALTH, the world's leader in data collection on pharmaceutical sales and prescriptions, in view of imposing interim measures on the company, following its refusal to grant a licence to its regional sales data method in Germany (where IMS has a dominant position). According to the Commission, this refusal is an abuse of a dominant position, preventing new competitors...